Quantum BioPharma Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a phase 2 clinical trial for Lucid-MS, a novel drug designed to protect and potentially repair the myelin sheath in patients with multiple sclerosis (MS). This marks the first human testing of a treatment with this specific mechanism of action, addressing a critical gap in current MS therapies, which primarily slow disease progression without reversing existing damage. The FDA approval follows the company’s 19.84% ownership stake in Unbuzzd Wellness Inc., a subsidiary that develops UNBUZZD, a wellness product generating royalty payments under a tiered structure: 7% on sales up to $250 million, dropping to 3% thereafter.
Quantum BioPharma Clears FDA for MS Phase 2 Trial, Eyes Lucid-MS Innovation
The FDA has approved Quantum BioPharma’s phase 2 trial for Lucid-MS, a first-in-class drug targeting myelin repair in multiple sclerosis, following the company’s 19.84% ownership stake in Unbuzzd Wellness Inc.
SL
Sophie Laurent · FX & Rates Desk · 16 Sept 2026 · 14:18 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
